KMTS · sample dossier
Kestra Medical Technologies, Ltd. Common Stock
60/100
OutdatedGenerated Sep 12, 2026 · 10:00 AM UTC · 55 days ago
This copy is frozen (Sep 12). Sign in to run the same work — filings, valuation, bull and bear, sources — on any US stock or ETF, in about 90 seconds.
Run a fresh dossierKMTS
EquityKestra Medical Technologies, Ltd. Common Stock · XNAS
Decision context
Recommendation
Balanced between solid Growth (100/100) and constrained Valuation (38/100).
A mixed picture — no strong reason to buy or sell right now.
AlphaDog Fair Value
Executive thesis & key metrics
Executive Investment Thesis
Kestra Medical Technologies, Ltd. is a medical device company with a market capitalization of $1.34B trading at a Price/Book of 5.14 and generating a gross margin of 51.4%. The Hold assessment reflects rapid top-line expansion with Revenue Growth YoY of 66.2% and low balance sheet leverage at 0.18 Debt/Equity, counterbalanced by negative profitability with a P/E ratio of -9.40 and EV/EBITDA of -9.44. The primary operational risk is severe cash burn, evidenced by a Net Margin of -138.4%-$2.01 (four-quarter statements) FCF/Share of -$1.29, and a 137.5% YoY surge in shares outstanding.
Key Metrics to Watch
What changed recently
No material changes found in the last 30 days.
Why this rating
Score 60 · Hold
Data through
OutdatedApr 30, 2026
Growth scores 100/100 — top-line expansion leads the profile.
Levels unavailable — AlphaDog quantitative valuation model did not produce an estimate from comps or DCF
Re-evaluate if
- Net margin falls below -110.7% (was -138.4%)
- Debt/Equity increases above 0.18.
Trim / reconsider if
- ROA falls below -16.7% (was -25.7%)
Think of these dollars as a map of our value estimate for Hold — helpful context, not a reason to override the view.
A Calmer Look · Devil's Advocate
The consensus Hold verdict dangerously understates the solvency risks of an enterprise converting every dollar of commercial revenue into a -138.4% net margin deficit.
May be overlooked
Financial disclosures from 2026-04-30 are over 130 days stale as of 2026-09-12, hiding subsequent cash depletion and the true runway before the next equity raise.
The low Debt/Equity ratio of 0.18 and Altman Z-score of 8.75 mask solvency fragility by capturing balance sheet liquidity created through a 137.5% YoY share dilution rather than self-sustaining cash flow.
Consensus treats a 51.4% gross margin as validation of device economics while ignoring that operating overhead overwhelms gross profit to produce an ROA of -25.7%.
Expectations look stretched
Projecting top-line expansion (47.9% quarterly revenue growth to $28.64M) into equity upside despite an operational profile generating -$1.29 in FCF per share.
Valuing an unprofitable business at a Price/Book ratio of 5.1 and a $1.34B market capitalization while its P/E remains deeply negative at -9.4.
Over-weighting a coordinated insider purchase of just 7,217 shares per executive on 2026-09-09 while disregarding trailing 3-month net insider selling of -$3.67M across 18 open-market sales.
Revenue Growth YoY decelerates below 66.2%.
Revenue Growth YoY decelerates below 66.2%.
Market context
Snapshot returns at report publication
1 month
-18.4%
3 months
+13.5%
6 months
+20.1%
1 year
+25.6%
At a Glance
A smaller company is in a pullback at unprofitable earnings.
Top Holders
Financial trajectory
Financial Performance
Go deeper
For learning and research only — not investment advice. AlphaDog doesn’t hold stocks and isn’t your financial advisor.
Run the next one yourself.
You just read a full KMTS dossier — scored verdict, valuation, and both sides, with sources. Sign in to run that on a name you hold, on current filings. A free account includes 10 credits a week, 1 per fresh run.